{"id":83051,"topic":"peptides","source":"Dealroom","title":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy - Dealroom","url":"https://app.dealroom.co/news/note/zealand-pharma-out-licenses-glp-1-gastrin-peptide-platform-to-elvinix-for-regenerative-type-1-diabetes-therapy","url_hash":"864df32ca08aa2423357f68f3c1c7dd25ee87872","author":"","summary":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy Dealroom","content":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy\n● 43 minutes agoWhat happened? On 15 September 2026, Zealand Pharma signed an exclusive licence agreement handing a GLP-1/gastrin dual-agonist peptide portfolio to Elvinix, a newly formed US biopharmaceutical company, which gains rights to develop and commercialise the platform as a regenerative therapy for type 1 diabetes. The deal transfers the underlying patent families and an extensive package of preclinical data, giving Elvinix the foundation to move the programme toward clinical development.\nWhy it matters: Type 1 diabetes, which affects an estimated 9.5 million people worldwide, is caused by the immune-driven loss of insulin-producing beta cells in the pancreas; today's insulin therapy manages the symptoms but does not restore the body's own insulin production. The licensed peptides combine a GLP-1 receptor agonist (a class better known for obesity and diabetes injections) with a gastrin agonist, chosen for the second molecule's role in regenerating and protecting beta cells. Elvinix is positioning the program as a potentially first-in-class, disease-modifying treatment that could reduce hypoglycaemia, complications and the burden of daily insulin. For Zealand, the out-licence sharpens focus on its core obesity pipeline (including petrelintintide and the Boehringer Ingelheim partnership) while monetising a platform it will not take into the clinic itself. \"This license gives us a peptide platform backed by years of rigorous preclinical work, freeing us to focus on what matters most: advancing a potentially first-in-class, disease-modifying therapy for type 1 diabetes,\" said Elvinix chief executive Daniil Koshelev.\nRead more: Business Wire, 15 September 2026 · Nordic Life Science, 15 September 2026","image_url":"https://webshotter.dealroom.co/?width=1600&height=800&wait_until=networkidle0&url=https%3A%2F%2Fapp.dealroom.co%2Fnews%2Fnote%2Fzealand-pharma-out-licenses-glp-1-gastrin-peptide-platform-to-elvinix-for-regenerative-type-1-diabetes-therapy%3Fscreenshot%3Dtrue","lang":"en","published_at":"2026-09-15T15:50:25+00:00","fetched_at":"2026-09-15T16:15:09+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy\n● 43 minutes agoWhat happened? On 15 September 2026, Zealand Pharma signed an exclusive licence agreement handing a GLP-1/gastrin dual-agonist peptide portfolio to Elvinix, a newly formed US biopharmaceutical company, which gains rights to develop and commercialise the platform as a regenerative therapy for type 1 diabetes.","cluster_id":null,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://app.dealroom.co/news/note/zealand-pharma-out-licenses-glp-1-gastrin-peptide-platform-to-elvinix-for-regenerative-type-1-diabetes-therapy","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 1844 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":1844,"summary_length":436,"usable_text_length":1844,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":1844,"summary_length":436}},"news_item":{"id":83051,"canonical_url":"https://app.dealroom.co/news/note/zealand-pharma-out-licenses-glp-1-gastrin-peptide-platform-to-elvinix-for-regenerative-type-1-diabetes-therapy","source_url":"https://app.dealroom.co/news/note/zealand-pharma-out-licenses-glp-1-gastrin-peptide-platform-to-elvinix-for-regenerative-type-1-diabetes-therapy","title":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy - Dealroom","source_name":"Dealroom","author":null,"published_at":"2026-09-15T15:50:25+00:00","locale":"en","topic":"peptides","tags":[],"rss_summary":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy Dealroom","full_text":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy\n● 43 minutes agoWhat happened? On 15 September 2026, Zealand Pharma signed an exclusive licence agreement handing a GLP-1/gastrin dual-agonist peptide portfolio to Elvinix, a newly formed US biopharmaceutical company, which gains rights to develop and commercialise the platform as a regenerative therapy for type 1 diabetes. The deal transfers the underlying patent families and an extensive package of preclinical data, giving Elvinix the foundation to move the programme toward clinical development.\nWhy it matters: Type 1 diabetes, which affects an estimated 9.5 million people worldwide, is caused by the immune-driven loss of insulin-producing beta cells in the pancreas; today's insulin therapy manages the symptoms but does not restore the body's own insulin production. The licensed peptides combine a GLP-1 receptor agonist (a class better known for obesity and diabetes injections) with a gastrin agonist, chosen for the second molecule's role in regenerating and protecting beta cells. Elvinix is positioning the program as a potentially first-in-class, disease-modifying treatment that could reduce hypoglycaemia, complications and the burden of daily insulin. For Zealand, the out-licence sharpens focus on its core obesity pipeline (including petrelintintide and the Boehringer Ingelheim partnership) while monetising a platform it will not take into the clinic itself. \"This license gives us a peptide platform backed by years of rigorous preclinical work, freeing us to focus on what matters most: advancing a potentially first-in-class, disease-modifying therapy for type 1 diabetes,\" said Elvinix chief executive Daniil Koshelev.\nRead more: Business Wire, 15 September 2026 · Nordic Life Science, 15 September 2026","excerpt":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy\n● 43 minutes agoWhat happened? On 15 September 2026, Zealand Pharma signed an exclusive licence agreement handing a GLP-1/gastrin dual-agonist peptide portfolio to Elvinix, a newly formed US biopharmaceutical company, which gains rights to develop and commercialise the platform as a regenerative therapy for type 1 diabetes.","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 1844 characters.","diagnostics_url":"/api/diagnose?url=https%3A//app.dealroom.co/news/note/zealand-pharma-out-licenses-glp-1-gastrin-peptide-platform-to-elvinix-for-regenerative-type-1-diabetes-therapy","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 1844 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":1844,"summary_length":436,"usable_text_length":1844,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":1844,"summary_length":436}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy - Dealroom","url":"https://app.dealroom.co/news/note/zealand-pharma-out-licenses-glp-1-gastrin-peptide-platform-to-elvinix-for-regenerative-type-1-diabetes-therapy","summary":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy\n● 43 minutes agoWhat happened? On 15 September 2026, Zealand Pharma signed an exclusive licence agreement handing a GLP-1/gastrin dual-agonist peptide portfolio to Elvinix, a newly formed US biopharmaceutical company, which gains rights to develop and commercialise the platform as a regenerative therapy for type 1 diabetes.","source":"Dealroom","date":"2026-09-15T15:50:25+00:00","content":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy\n● 43 minutes agoWhat happened? On 15 September 2026, Zealand Pharma signed an exclusive licence agreement handing a GLP-1/gastrin dual-agonist peptide portfolio to Elvinix, a newly formed US biopharmaceutical company, which gains rights to develop and commercialise the platform as a regenerative therapy for type 1 diabetes. The deal transfers the underlying patent families and an extensive package of preclinical data, giving Elvinix the foundation to move the programme toward clinical development.\nWhy it matters: Type 1 diabetes, which affects an estimated 9.5 million people worldwide, is caused by the immune-driven loss of insulin-producing beta cells in the pancreas; today's insulin therapy manages the symptoms but does not restore the body's own insulin production. The licensed peptides combine a GLP-1 receptor agonist (a class better known for obesity and diabetes injections) with a gastrin agonist, chosen for the second molecule's role in regenerating and protecting beta cells. Elvinix is positioning the program as a potentially first-in-class, disease-modifying treatment that could reduce hypoglycaemia, complications and the burden of daily insulin. For Zealand, the out-licence sharpens focus on its core obesity pipeline (including petrelintintide and the Boehringer Ingelheim partnership) while monetising a platform it will not take into the clinic itself. \"This license gives us a peptide platform backed by years of rigorous preclinical work, freeing us to focus on what matters most: advancing a potentially first-in-class, disease-modifying therapy for type 1 diabetes,\" said Elvinix chief executive Daniil Koshelev.\nRead more: Business Wire, 15 September 2026 · Nordic Life Science, 15 September 2026","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//app.dealroom.co/news/note/zealand-pharma-out-licenses-glp-1-gastrin-peptide-platform-to-elvinix-for-regenerative-type-1-diabetes-therapy","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 1844 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 1844 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":1844,"summary_length":436,"usable_text_length":1844,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":1844,"summary_length":436}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/83051","export_markdown":"/api/items/83051/export?format=markdown","export_json":"/api/items/83051/export?format=json","diagnose":"/api/diagnose?url=https%3A//app.dealroom.co/news/note/zealand-pharma-out-licenses-glp-1-gastrin-peptide-platform-to-elvinix-for-regenerative-type-1-diabetes-therapy"},"formats":{"full":{"id":83051,"title":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy - Dealroom","url":"https://app.dealroom.co/news/note/zealand-pharma-out-licenses-glp-1-gastrin-peptide-platform-to-elvinix-for-regenerative-type-1-diabetes-therapy","source":"Dealroom","author":null,"published_at":"2026-09-15T15:50:25+00:00","locale":"en","topic":"peptides","tags":[],"excerpt":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy\n● 43 minutes agoWhat happened? On 15 September 2026, Zealand Pharma signed an exclusive licence agreement handing a GLP-1/gastrin dual-agonist peptide portfolio to Elvinix, a newly formed US biopharmaceutical company, which gains rights to develop and commercialise the platform as a regenerative therapy for type 1 diabetes.","full_text":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy\n● 43 minutes agoWhat happened? On 15 September 2026, Zealand Pharma signed an exclusive licence agreement handing a GLP-1/gastrin dual-agonist peptide portfolio to Elvinix, a newly formed US biopharmaceutical company, which gains rights to develop and commercialise the platform as a regenerative therapy for type 1 diabetes. The deal transfers the underlying patent families and an extensive package of preclinical data, giving Elvinix the foundation to move the programme toward clinical development.\nWhy it matters: Type 1 diabetes, which affects an estimated 9.5 million people worldwide, is caused by the immune-driven loss of insulin-producing beta cells in the pancreas; today's insulin therapy manages the symptoms but does not restore the body's own insulin production. The licensed peptides combine a GLP-1 receptor agonist (a class better known for obesity and diabetes injections) with a gastrin agonist, chosen for the second molecule's role in regenerating and protecting beta cells. Elvinix is positioning the program as a potentially first-in-class, disease-modifying treatment that could reduce hypoglycaemia, complications and the burden of daily insulin. For Zealand, the out-licence sharpens focus on its core obesity pipeline (including petrelintintide and the Boehringer Ingelheim partnership) while monetising a platform it will not take into the clinic itself. \"This license gives us a peptide platform backed by years of rigorous preclinical work, freeing us to focus on what matters most: advancing a potentially first-in-class, disease-modifying therapy for type 1 diabetes,\" said Elvinix chief executive Daniil Koshelev.\nRead more: Business Wire, 15 September 2026 · Nordic Life Science, 15 September 2026","reading_time_min":1,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 1844 characters.","diagnostics_url":"/api/diagnose?url=https%3A//app.dealroom.co/news/note/zealand-pharma-out-licenses-glp-1-gastrin-peptide-platform-to-elvinix-for-regenerative-type-1-diabetes-therapy","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 1844 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":1844,"summary_length":436,"usable_text_length":1844,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":1844,"summary_length":436}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 1844 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":1844,"summary_length":436,"usable_text_length":1844,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":1844,"summary_length":436}},"actions":{"read":"/item/83051","export_markdown":"/api/items/83051/export?format=markdown","export_json":"/api/items/83051/export?format=json","diagnose":"/api/diagnose?url=https%3A//app.dealroom.co/news/note/zealand-pharma-out-licenses-glp-1-gastrin-peptide-platform-to-elvinix-for-regenerative-type-1-diabetes-therapy"}},"digest":{"id":83051,"title":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy - Dealroom","url":"https://app.dealroom.co/news/note/zealand-pharma-out-licenses-glp-1-gastrin-peptide-platform-to-elvinix-for-regenerative-type-1-diabetes-therapy","source":"Dealroom","topic":"peptides","published_at":"2026-09-15T15:50:25+00:00","excerpt":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy ● 43 minutes agoWhat happened? On 15 September 2026, Zealand Pharma signed an exclusive licence agreement handing a GLP-1/gastrin dual-agonist peptide portfolio to…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 1844 characters.","reading_time_min":1,"cluster_id":null},"card":{"display_title":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy - Dealroom","subtitle":"Dealroom · 2026-09-15","summary":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy ● 43 minutes agoWhat happened? On 15 September 2026, Zealand Pharma signed an exclusive licence agreement…","badges":["quality:high"],"links":{"read":"/item/83051","original":"https://app.dealroom.co/news/note/zealand-pharma-out-licenses-glp-1-gastrin-peptide-platform-to-elvinix-for-regenerative-type-1-diabetes-therapy","diagnose":"/api/diagnose?url=https%3A//app.dealroom.co/news/note/zealand-pharma-out-licenses-glp-1-gastrin-peptide-platform-to-elvinix-for-regenerative-type-1-diabetes-therapy"},"quality_warning":null},"export":{"title":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy - Dealroom","url":"https://app.dealroom.co/news/note/zealand-pharma-out-licenses-glp-1-gastrin-peptide-platform-to-elvinix-for-regenerative-type-1-diabetes-therapy","summary":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy\n● 43 minutes agoWhat happened? On 15 September 2026, Zealand Pharma signed an exclusive licence agreement handing a GLP-1/gastrin dual-agonist peptide portfolio to Elvinix, a newly formed US biopharmaceutical company, which gains rights to develop and commercialise the platform as a regenerative therapy for type 1 diabetes.","source":"Dealroom","date":"2026-09-15T15:50:25+00:00","content":"Zealand Pharma out-licenses GLP-1/gastrin peptide platform to Elvinix for regenerative type 1 diabetes therapy\n● 43 minutes agoWhat happened? On 15 September 2026, Zealand Pharma signed an exclusive licence agreement handing a GLP-1/gastrin dual-agonist peptide portfolio to Elvinix, a newly formed US biopharmaceutical company, which gains rights to develop and commercialise the platform as a regenerative therapy for type 1 diabetes. The deal transfers the underlying patent families and an extensive package of preclinical data, giving Elvinix the foundation to move the programme toward clinical development.\nWhy it matters: Type 1 diabetes, which affects an estimated 9.5 million people worldwide, is caused by the immune-driven loss of insulin-producing beta cells in the pancreas; today's insulin therapy manages the symptoms but does not restore the body's own insulin production. The licensed peptides combine a GLP-1 receptor agonist (a class better known for obesity and diabetes injections) with a gastrin agonist, chosen for the second molecule's role in regenerating and protecting beta cells. Elvinix is positioning the program as a potentially first-in-class, disease-modifying treatment that could reduce hypoglycaemia, complications and the burden of daily insulin. For Zealand, the out-licence sharpens focus on its core obesity pipeline (including petrelintintide and the Boehringer Ingelheim partnership) while monetising a platform it will not take into the clinic itself. \"This license gives us a peptide platform backed by years of rigorous preclinical work, freeing us to focus on what matters most: advancing a potentially first-in-class, disease-modifying therapy for type 1 diabetes,\" said Elvinix chief executive Daniil Koshelev.\nRead more: Business Wire, 15 September 2026 · Nordic Life Science, 15 September 2026","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//app.dealroom.co/news/note/zealand-pharma-out-licenses-glp-1-gastrin-peptide-platform-to-elvinix-for-regenerative-type-1-diabetes-therapy","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 1844 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 1844 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":1844,"summary_length":436,"usable_text_length":1844,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":1844,"summary_length":436}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}